Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Baucus blinks, CER is out, PCOR is in

September 14, 2010
By Ronald Piana
Article

In today’s heated healthcare debate, nuance matters, so does public perception. The term comparative effectiveness research, once the darling of policy wonks, had perception problems right out of the gate. So, the research stays, but the term goes.

In today’s heated healthcare debate, nuance matters, so does public perception. The term comparative effectiveness research, once the darling of policy wonks, had perception problems right out of the gate. So, the research stays, but the term goes.

As the debate on creating a public/private entity to conduct comparative effectiveness research was heating up, Senate Finance Committee Chairman Max Baucus (D-Mt.) decided that the term “comparative effectiveness research” was becoming too controversial and rebranded the term in health care reform legislation to “patient-centered outcomes research.”

In short, CER had become too linked to issues such as whether research data would limit physician’s latitude for prescribing and whether costs might play a determining role.

The rebranding effort appears to be taking off now that health care reform is law and “PCORI”-as the Patient-Centered Outcomes Research Institute is called-is being implemented.

HHS embraced the terminology revamp with its Sept. 1 announcement of grants to bolster research capabilities in health facilities, with a focus on diverse populations. The announcement says the $17 million in awards will go toward “patient-centered outcomes research” or PCOR. Interestingly, the entire release eschews the loaded CER terminology, save for a link for more information on "about patient-centered and comparative effectiveness research" in the second to last sentence.

CER/PCOR stakeholders are now eagerly watching for HHS to name the first board members of the Patient-Centered Outcomes Research Institute, created as part of the health reform initiative. One key issue facing the group is how to effectively disseminate research findings. Who knows? Perhaps research branded as PCOR will be more effective than that branded as CER.


 

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content
Advertisement

Six or More Cycles of Chemo Prolong Survival with Atezolizumab in ES-SCLC

Six or More Cycles of Chemo Prolong Survival with Atezolizumab in ES-SCLC

Tim Cortese
June 4th 2025
Article

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Ashling Wahner
June 3rd 2025
Article

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.


No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

Related Content
Advertisement

Six or More Cycles of Chemo Prolong Survival with Atezolizumab in ES-SCLC

Six or More Cycles of Chemo Prolong Survival with Atezolizumab in ES-SCLC

Tim Cortese
June 4th 2025
Article

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Ashling Wahner
June 3rd 2025
Article

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.


No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

No Improvement in RFS With Adjuvant Nivolumab/Relatlimab in Advanced Melanoma

Kristi Rosa
June 3rd 2025
Article

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.